schliessen

Filtern

 

Bibliotheken

Sirolimus in pediatric renal transplantation

Kasap B. Sirolimus in pediatric renal transplantation. 
Pediatr Transplantation 2011: 15: 673–685. © 2011 John Wiley & Sons A/S. SRL, an mTOR inhibitor that inhibits cell cycle progression, represents an important alternative to CNIs, which are still the cornerstones of pediatric solid organ tx. Bec... Full description

Journal Title: Pediatric Transplantation November 2011, Vol.15(7), pp.673-685
Main Author: Kasap, Belde
Format: Electronic Article Electronic Article
Language:
Subjects:
ID: ISSN: 1397-3142 ; E-ISSN: 1399-3046 ; DOI: 10.1111/j.1399-3046.2011.01575.x
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: wj10.1111/j.1399-3046.2011.01575.x
title: Sirolimus in pediatric renal transplantation
format: Article
creator:
  • Kasap, Belde
subjects:
  • Sirolimus
  • Pediatric Renal Transplantation
ispartof: Pediatric Transplantation, November 2011, Vol.15(7), pp.673-685
description: Kasap B. Sirolimus in pediatric renal transplantation. 
Pediatr Transplantation 2011: 15: 673–685. © 2011 John Wiley & Sons A/S. SRL, an mTOR inhibitor that inhibits cell cycle progression, represents an important alternative to CNIs, which are still the cornerstones of pediatric solid organ tx. Because there are still limited data on SRL use among pediatric solid organ recipients, further studies are needed to verify the efficacy and safety of SRL. It has unique pharmacokinetic characteristics concerning dosing intervals and reduction of the dose in combination with other immunosuppressants. SRL also has antineoplastic, antiviral, and antiatherogenic advantages over other immunosuppressive agents. The adverse effects of SRL including thrombocytopenia, hyperlipidemia, proteinuria, impaired wound healing, mouth ulcers, edema, male hypogonadism, TMA, and interstitial pneumonitis must be considered carefully in pediatric population. This article reviews the most recent data on SRL application in the field of pediatric renal tx.
language:
source:
identifier: ISSN: 1397-3142 ; E-ISSN: 1399-3046 ; DOI: 10.1111/j.1399-3046.2011.01575.x
fulltext: fulltext
issn:
  • 1397-3142
  • 13973142
  • 1399-3046
  • 13993046
url: Link


@attributes
ID803542954
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.1111/j.1399-3046.2011.01575.x
sourceidwj
recordidTN_wj10.1111/j.1399-3046.2011.01575.x
sourcesystemOther
pqid899143567
galeid269927690
display
typearticle
titleSirolimus in pediatric renal transplantation
creatorKasap, Belde
ispartofPediatric Transplantation, November 2011, Vol.15(7), pp.673-685
identifier
subjectSirolimus ; Pediatric Renal Transplantation
descriptionKasap B. Sirolimus in pediatric renal transplantation. 
Pediatr Transplantation 2011: 15: 673–685. © 2011 John Wiley & Sons A/S. SRL, an mTOR inhibitor that inhibits cell cycle progression, represents an important alternative to CNIs, which are still the cornerstones of pediatric solid organ tx. Because there are still limited data on SRL use among pediatric solid organ recipients, further studies are needed to verify the efficacy and safety of SRL. It has unique pharmacokinetic characteristics concerning dosing intervals and reduction of the dose in combination with other immunosuppressants. SRL also has antineoplastic, antiviral, and antiatherogenic advantages over other immunosuppressive agents. The adverse effects of SRL including thrombocytopenia, hyperlipidemia, proteinuria, impaired wound healing, mouth ulcers, edema, male hypogonadism, TMA, and interstitial pneumonitis must be considered carefully in pediatric population. This article reviews the most recent data on SRL application in the field of pediatric renal tx.
source
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
search
creatorcontribKasap, Belde
titleSirolimus in pediatric renal transplantation
descriptionKasap B. Sirolimus in pediatric renal transplantation. 
Pediatr Transplantation 2011: 15: 673–685. © 2011 John Wiley & Sons A/S. SRL, an mTOR inhibitor that inhibits cell cycle progression, represents an important alternative to CNIs, which are still the cornerstones of pediatric solid organ tx. Because there are still limited data on SRL use among pediatric solid organ recipients, further studies are needed to verify the efficacy and safety of SRL. It has unique pharmacokinetic characteristics concerning dosing intervals and reduction of the dose in combination with other immunosuppressants. SRL also has antineoplastic, antiviral, and antiatherogenic advantages over other immunosuppressive agents. The adverse effects of SRL including thrombocytopenia, hyperlipidemia, proteinuria, impaired wound healing, mouth ulcers, edema, male hypogonadism, TMA, and interstitial pneumonitis must be considered carefully in pediatric population. This article reviews the most recent data on SRL application in the field of pediatric renal tx.
subject
0Sirolimus
1Pediatric Renal Transplantation
general
0Blackwell Publishing Ltd
110.1111/j.1399-3046.2011.01575.x
2Wiley Online Library
sourceidwj
recordidwj10.1111/j.1399-3046.2011.01575.x
issn
01397-3142
113973142
21399-3046
313993046
rsrctypearticle
creationdate2011
addtitlePediatric Transplantation
searchscope
0wj
1wiley
scope
0wj
1wiley
lsr30VSR-Enriched:[pqid, pages, galeid]
sort
titleSirolimus in pediatric renal transplantation
authorKasap, Belde
creationdate20111100
facets
frbrgroupid3482254768211062538
frbrtype5
creationdate2011
topic
0Sirolimus
1Pediatric Renal Transplantation
collectionWiley Online Library
prefilterarticles
rsrctypearticles
creatorcontribKasap, Belde
jtitlePediatric Transplantation
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulastKasap
aufirstBelde
auKasap, Belde
atitleSirolimus in pediatric renal transplantation
jtitlePediatric Transplantation
risdate201111
volume15
issue7
spage673
epage685
issn1397-3142
eissn1399-3046
genrearticle
ristypeJOUR
abstractKasap B. Sirolimus in pediatric renal transplantation. 
Pediatr Transplantation 2011: 15: 673–685. © 2011 John Wiley & Sons A/S. SRL, an mTOR inhibitor that inhibits cell cycle progression, represents an important alternative to CNIs, which are still the cornerstones of pediatric solid organ tx. Because there are still limited data on SRL use among pediatric solid organ recipients, further studies are needed to verify the efficacy and safety of SRL. It has unique pharmacokinetic characteristics concerning dosing intervals and reduction of the dose in combination with other immunosuppressants. SRL also has antineoplastic, antiviral, and antiatherogenic advantages over other immunosuppressive agents. The adverse effects of SRL including thrombocytopenia, hyperlipidemia, proteinuria, impaired wound healing, mouth ulcers, edema, male hypogonadism, TMA, and interstitial pneumonitis must be considered carefully in pediatric population. This article reviews the most recent data on SRL application in the field of pediatric renal tx.
copOxford, UK
pubBlackwell Publishing Ltd
doi10.1111/j.1399-3046.2011.01575.x
pages673-685
date2011-11